[1]齐保玉,魏戌,朱立国,等.血管生成在骨代谢及骨质疏松症中的作用研究进展[J].国际内分泌代谢杂志,2021,41(02):128-132.[doi:10.3760/cma.j.cn121383-20200326-03066]
　Qi Baoyu,Wei Xu,Zhu Liguo,et al.Research progress on the role of angiogenesis in bone metabolism and osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(02):128-132.[doi:10.3760/cma.j.cn121383-20200326-03066]
点击复制

血管生成在骨代谢及骨质疏松症中的作用研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年02期
页码:
128-132
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
Research progress on the role of angiogenesis in bone metabolism and osteoporosis
作者:
齐保玉1; 2; 魏戌1; 2; 朱立国1; 2; 戴建业3; 孙凯1; 2; 银河1; 2; 章轶立4
1中国中医科学院望京医院脊柱二科,北京 100102; 2中医正骨技术北京市重点实验室 100007; 3兰州大学药学院 730020; 4北京中医药大学中医学院 100029
Author(s):
Qi Baoyu1; 2;  Wei Xu1; 2;  Zhu Liguo1; 2;  Dai Jianye3;  Sun Kai1; 2;  Yin He1; 2;  Zhang Yili4.
1Orthopedics Department of Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China; 2Beijing Key Laboratory of Orthopedics of Traditional Chinese Medicine, Beijing, 100007, China; 3School of Pha
关键词:
骨质疏松症;  骨代谢;  成骨细胞;  破骨细胞
Keywords:
Angiogenesis;  Osteoporosis;  Bone metabolism;  Osteoblast;  Osteoclast
DOI:
10.3760/cma.j.cn121383-20200326-03066
摘要:
目前,骨质疏松症(OP)的防治主要集中于抑制骨吸收,但其局限性已显现。近年文献报道,血管生成与OP关系密切,而且发现血管生成与骨代谢间存在特定的“耦合”关系。血管生成,尤其是H型血管,可能通过影响骨形成、骨吸收及骨重塑进程的方式,在OP发生、发展及防治过程中发挥着重要的调节作用。本文重点梳理血管生成与骨代谢和OP之间的关系,可更全面、系统地认识OP,为其防治研究提供新的思路和理论支撑。
Abstract:
At present, the prevention and treatment of osteoporosis(OP)is mainly focus on the inhibition of bone resorption, and the limitations have now emerged. In recent years, it has been reported that angiogenesis is closely related to OP, and there is a specific coupling relationship between angiogenesis and bone metabolism. Angiogenesis, especially H-type blood vessels, may play an important regulatory role in the occurrence, development, and prevention of OP by influencing bone formation, resorption and remodeling. This article focuses on sorting out the relationship between angiogenesis and bone metabolism as well as OP, in order to understand OP disease more comprehensively and systematically, and provide new ideas and theoretical supports for studies of the prevention and treatment of OP.

参考文献/References:

[1] Watson EC,Adams RH. Biology of bone: the vasculature of the skeletal system[J].Cold Spring Harb Perspect Med,2018,8(7):a31559.DOI:10.1101/cshperspect.a031559.
[2] Sivaraj KK,Adams RH. Blood vessel formation and function in bone[J].Development,2016,143(15):2706-2715.DOI:10.1242/dev.136861.
[3] Stegen S,Carmeliet G. The skeletal vascular system-breathing life into bone tissue[J].Bone,2018,115:50-58.DOI:10.1016/j.bone.2017.08.022.
[4] Jia P,Zuo GL,Zhang LF,et al. Dimethyloxalylglycine prevents bone loss in ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis[J].PloS One,2014,9(11):e112744.DOI:10.1371/journal.pone.0112744.
[5] Maes C. Role and regulation of vascularization processes in endochondral bones[J].Calcif Tissue Int,2013,92(4):307-323.DOI:10.1007/s00223-012-9689-z.
[6] Kronenberg HM. Developmental regulation of the growth plate[J].Nature,2003,423(6937):332-336.DOI:10.1038/nature01657.
[7] Kusumbe AP,Ramasamy SK,Itkin T,et al. Age-dependent modulation of vascular niches for haematopoietic stem cells[J].Nature,2016,532(7599):380-384.DOI:10.1038/nature17638.
[8] Rumney RMH,Lanham SA,Kanczler JM,et al. In vivo delivery of VEGF RNA and protein to increase osteogenesis and intraosseous angiogenesis[J].Sci Rep,2019,9(1):17745.DOI:10.1038/s41598-019-53249-4.
[9] Behr B,Leucht P,Longaker MT,et al. Fgf-9 is required for angiogenesis and osteogenesis in long bone repair[J].Proc Natl Acad Sci USA,2010,107(26):11853-11858.DOI:10.1073/pnas.1003317107.
[10] Xu R,Yallowitz A,Qin A,et al. Targeting skeletal endothelium to ameliorate bone loss[J].Nat Med,2018,24(6):823-833.DOI:10.1038/s41591-018-0020-z.
[11] Hendrijantini N,Rostiny R,Kuntjoro M,et al. The effect of combination spirulina-chitosan on angiogenesis,osteoclast,and osteoblast cells in socket models of hyperglycemic rattus norvegicus[J].Contemp Clin Dent,2018,9(4):582-586.DOI:10.4103/ccd.ccd_617_18.
[12] Song C,Cao J,Lei Y,et al. Nuciferine prevents bone loss by disrupting multinucleated osteoclast formation and promoting type H vessel formation[J].FASEB J,2020,34(3):4798-4811.DOI:10.1096/fj.201902551R.
[13] Huang J,Yin H,Rao SS,et al. Harmine enhances type H vessel formation and prevents bone loss in ovariectomized mice[J].Theranostics,2018,8(9):2435-2446.DOI:10.7150/thno.22144.
[14] Hu K,Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair[J].J Clin Invest,2016,126(2):509-526.DOI:10.1172/JCI82585.
[15] Quan H,Liang M,Li N,et al. LncRNA-AK131850 sponges MiR-93-5p in newborn and mature osteoclasts to enhance the secretion of vascular endothelial growth factor a promoting vasculogenesis of endothelial progenitor cells[J].Cell Physiol Biochem,2018,46(1):401-417.DOI:10.1159/000488474.
[16] McClung M,Harris ST,Miller PD,et al. Bisphosphonate therapy for osteoporosis:benefits,risks,and drug holiday[J].Am J Med,2013,126(1):13-20.DOI:10.1016/j.amjmed.2012.06.023.
[17] Gao SY,Zheng GS,Wang L,et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB[J].PloS one,2017,12(6):e179248.DOI:10.1371/journal.pone.0179248.
[18] Zhou S,Bueno EM,Kim SW,et al. Effects of age on parathyroid hormone signaling in human marrow stromal cells[J].Aging Cell,2011,10(5):780-788.DOI:10.1111/j.1474-9726.2011.00717.x.
[19] Vahle JL,Sato M,Long GG,et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34)for 2 years and relevance to human safety[J].Toxicol Pathol,2002,30(3):312-321.DOI:10.1080/01926230252929882.
[20] 王亮,盛茂,袁晔,等.骨内H型血管在去势骨质疏松症模型中的变化[J].中华骨科杂志,2020,40(13):873-879.DOI:10.3760/cma.j.cn121113-20200305-00132.
[21] Guo C,Yang K,Yan Y,et al. SF-deferoxamine,a bone-seeking angiogenic drug,prevents bone loss in estrogen-deficient mice[J].Bone,2019,120:156-165.DOI:10.1016/j.bone.2018.10.025.
[22] Huang J,Lin D,Wei Z,et al. Parathyroid hormone derivative with reduced osteoclastic activity promoted bone regeneration via synergistic bone remodeling and angiogenesis[J].Small,2020,16(6):e1905876.DOI:10.1002/smll.201905876.
[23] 王亮,张鹏,姚喆,等.骨组织H亚型血管在骨质疏松与非骨质疏松骨折患者中的表现[J].中华骨科杂志,2016,36(20):1327-1334.DOI:10.3760/cma.j.issn.0253-2352.2016. 20.007.
[24] Veeriah V,Paone R,Chatterjee S,et al. Osteoblasts regulate angiogenesis in response to mechanical unloading[J].Calcif Tissue Int,2019,104(3):344-354.DOI:10.1007/s00223-018-0496-z.
[25] Lin J,Ji B,Zhang Y. Role of metformin on osteoblast differentiation in type 2 diabetes[J].Biomed Res Int,2019,2019:9203934.DOI:10.1155/2019/9203934.
[26] 王翔,谢屹.辛伐他汀对糖尿病并微血管病变骨代谢应激氧化及肾功能的影响[J].山西医药杂志,2016,45(21):2537-2539.DOI:10.3969/j.issn.0253-9926.2016.21.029.
[27] 黄妙玲,杜钢.探讨维格列汀对糖尿病患者骨质疏松及微血管病变的影响[J].河北医学,2019,25(10):1721-1724.DOI:10.3969/j.issn.1006-6233.2019.10.035.
[28] Xie H,Cui Z,Wang L,et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis[J].Nat Med,2014,20(11):1270-1278.DOI:10.1038/nm.3668.

相似文献/References:

[1]马骥,都健.代谢手术影响骨代谢的机制研究[J].国际内分泌代谢杂志,2017,37(05):312.
　Ma Ji,Du Jian..Mechanism study of effects of metabolic surgery on bone metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(02):312.
[2]乾贝贝 闫彩凤.SGLTs抑制剂对骨代谢的影响及其机制[J].国际内分泌代谢杂志,2019,39(06):422.[doi:10.3760/cma.j.issn.1673-4157.2019.06.015]
　Qian Beibei,Yan Caifeng.Impact of SGLTs inhibitors on bone metabolism and its mechanism[J].International Journal of Endocrinology and Metabolism,2019,39(02):422.[doi:10.3760/cma.j.issn.1673-4157.2019.06.015]
[3]梁珊珊 刘昊凌 高昕媛 辛玉晶.2型糖尿病合并下肢动脉疾病患者 血清FGF-23与骨钙素的关系研究[J].国际内分泌代谢杂志,2020,40(01):10.[doi:10.3760/cma.j.issn.1673-4157.2020.01.003]
　Liang Shanshan,Liu Haoling,Gao Xinyuan,et al.Relationship between serum FGF-23 and osteocalcin in patients with type 2 diabetes mellitus complicated with lower extremity arterial disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):10.[doi:10.3760/cma.j.issn.1673-4157.2020.01.003]
[4]杨婷,岳月仪,范雨佳,等.WISP1与骨质疏松症关系的研究进展[J].国际内分泌代谢杂志,2021,41(03):224.[doi:10.3760/cma.j.cn121383-20200417-04051]
　Yang Ting,Yue Yueyi,Fan Yujia,et al.Research progress on the relationship between WISP1 and osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(02):224.[doi:10.3760/cma.j.cn121383-20200417-04051]
[5]晁爱军.地舒单抗和罗莫佐单抗治疗骨质疏松症的进展及展望[J].国际内分泌代谢杂志,2023,43(04):283.[doi:10.3760/cma.j.cn121383-20230708-07013]
　Chao Aijun.Progress and prospects of denosumab and romosozumab in osteoporosis treatment[J].International Journal of Endocrinology and Metabolism,2023,43(02):283.[doi:10.3760/cma.j.cn121383-20230708-07013]
[6]温娟娟,张景云,吕文韬,等.卡格列净对超重及肥胖2型糖尿病患者骨代谢指标的影响[J].国际内分泌代谢杂志,2024,44(01):5.[doi:10.3760/cma.j.cn121383-20221120-11054]
　Wen Juanjuan,Zhang Jingyun,Lyu Wentao,et al.Effect of SGLT-2 inhibitor on bone turnover markers in overweight and obese patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2024,44(02):5.[doi:10.3760/cma.j.cn121383-20221120-11054]
[7]杨泓娟,龚恬,项守奎.皮肤与骨质疏松症[J].国际内分泌代谢杂志,2024,44(03):202.[doi:10.3760/cma.j.cn121383-20230830-08074]
　Yang Hongjuan,Gong Tian,Xiang Shoukui..Skin and Osteoporosis[J].International Journal of Endocrinology and Metabolism,2024,44(02):202.[doi:10.3760/cma.j.cn121383-20230830-08074]

备注/Memo

备注/Memo:
通信作者:魏戌, Email:weixu.007@163.com 基金项目:国家自然科学基金(81704102); 中国博士后科学基金(2019M662284); 国家中医药领军人才支持计划——“岐黄学者”计划; 中华中医药学会(2017—2019年度)青年人才托举工程项目(CACM-2017-QNRC2-A03); 中国中医科学院“十三五”重点领域科研项目(ZZ10-022); 江西省博士后研究人员择优资助科研项目(2019KY18)
更新日期/Last Update: 2021-03-20